Advertisement

Breast Cancer

, Volume 23, Issue 3, pp 367–377 | Cite as

The Japanese Breast Cancer Society clinical practice guideline for surgical treatment of breast cancer, 2015 edition

  • Hiromitsu JinnoEmail author
  • Masafumi Inokuchi
  • Toshikazu Ito
  • Kaoru Kitamura
  • Goro Kutomi
  • Takehiko Sakai
  • Yuko Kijima
  • Noriaki Wada
  • Yoshinori Ito
  • Hirofumi Mukai
Special Feature Japanese Breast Cancer Society Guidelines 2015

Introduction

In the Clinical Practice Guideline for Surgical Treatment of Breast Cancer, clinical questions (CQs) were divided into 6 categories: (1) breast-conserving therapy (BCT); (2) axillary lymph node dissection (ALND) and sentinel lymph node biopsy (SLNB); (3) less invasive treatments (endoscopic surgery and non-surgical ablation); (4) breast reconstruction; (5) surgical treatment for advanced and metastatic breast cancer; and (6) others.

Major revisions to the 2015 edition were as follows: positive surgical margins for breast-conserving surgery were defined as ink on invasive or in situ cancer in CQ3; SLNB using indocyanine green (ICG) fluorescence imaging was newly described in CQ10; and recommendations were updated for CQ18 and 28.

Breast-conserving therapy

BCT refers to breast-conserving surgery (BCS), followed by radiation therapy (RT) to eradicate any microscopic residual disease. From 1972 to 1989, 6 randomized, controlled trials (RCTs) comparing BCT with mastectomy were...

Keywords

Breast Cancer Brain Metastasis Sentinel Lymph Node Biopsy Lymphedema Axillary Lymph Node Dissection 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Compliance with ethical standards

Conflict of interest

Yoshinori Ito received lecture fees from Chugai, Esai, and Novartis and research grants from Novartis, Chugai, Parexel, Esai, Sanofi, Taiho, EPS, Dai-ichi-sankyo, and Boehringer-ingelheim. The other authors declared no potential conflicts of interest.

References

  1. 1.
    Fisher B, Anderson S, Bryant J, Margolese G, Deutsch M, Fisher ER, et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med. 2002;347:1233–41.CrossRefPubMedGoogle Scholar
  2. 2.
    Veronesi U, Cascinelli N, Mariani L, Greco M, Saccozzi R, Luini A, et al. Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. N Engl J Med. 2002;347:1227–32.CrossRefPubMedGoogle Scholar
  3. 3.
    Virnig BA, Tuttle TM, Shamliyan T, Kane RL. Ductal carcinoma in situ of the breast: a systematic review of incidence, treatment, and outcomes. J Natl Cancer Inst. 2010;102:170–8.CrossRefPubMedGoogle Scholar
  4. 4.
    Clarke M, Collins R, Darby S, Davies C, Elphinstone P, Evans V, et al. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;366:2087–106.CrossRefPubMedGoogle Scholar
  5. 5.
    Silverstein MJ, Lagios MD, Craig PH, Waisman JR, Lewinsky BS, Colburn WJ, et al. A prognostic index for ductal carcinoma in situ of the breast. Cancer. 1996;77:2267–74.CrossRefPubMedGoogle Scholar
  6. 6.
    Moran MS, Schnitt SJ, Giuliano AE, Harris JR, Khan SA, Horton J, et al. Society of Surgical Oncology; American Society for Radiation Oncology. Society of Surgical Oncology-American Society for Radiation Oncology consensus guideline on margins for breast-conserving surgery with whole-breast irradiation in stages I and II invasive breast cancer. J Clin Oncol. 2014;32:1507–15.CrossRefPubMedGoogle Scholar
  7. 7.
    Mauri D, Pavlidis N, Ioannidis JP. Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis. J Natl Cancer Inst. 2005;97:188–94.CrossRefPubMedGoogle Scholar
  8. 8.
    Akashi-Tanaka S, Fukutomi T, Sato N, Iwamoto E, Watanabe T, Katsumata N, et al. The use of contrast-enhanced computed tomography before neoadjuvant chemotherapy to identify patients likely to be treated safely with breast-conserving surgery. Ann Surg. 2004;239:238–43.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Tozaki M, Kobayashi T, Uno S, Aiba K, Takeyama H, Shioya H, et al. Breast-conserving surgery after chemotherapy: value of MDCT for determining tumor distribution and shrinkage pattern. Am J Roentgenol. 2006;186:431–9.CrossRefGoogle Scholar
  10. 10.
    Ishitobi M, Komoike Y, Nakahara S, Motomura K, Koyama H, Inaji H. Repeat lumpectomy for ipsilateral breast tumor recurrence after breast-conserving treatment. Oncology. 2011;81:381–6.CrossRefPubMedGoogle Scholar
  11. 11.
    Lanitis S, Tekkis PP, Sgourakis G, Dimopoulos N, Al Mufti R, Hadjiminas DJ. Comparison of skin-sparing mastectomy versus non-skin-sparing mastectomy for breast cancer: a meta-analysis of observational studies. Ann Surg. 2010;251:632–9.CrossRefPubMedGoogle Scholar
  12. 12.
    Paepke S, Schmid R, Fleckner S, Paepke D, Niemeyer M, Schmalfeldt B, et al. Subcutaneous mastectomy with conservation of the nipple-areola skin: broadening the indications. Ann Surg. 2009;250:288–92.CrossRefPubMedGoogle Scholar
  13. 13.
    Fisher B, Jeong JH, Anderson S, Bryant J, Fisher ER, Wolmark N. Twenty-five-year follow-up of a randomized trial comparing radical mastectomy, total mastectomy, and total mastectomy followed by irradiation. N Engl J Med. 2002;347:567–75.CrossRefPubMedGoogle Scholar
  14. 14.
    Orr RK. The impact of prophylactic axillary node dissection on breast cancer survival-a Bayesian meta-analysis. Ann Surg Oncol. 1999;6:109–16.CrossRefPubMedGoogle Scholar
  15. 15.
    Rosen PP, Lesser ML, Kinne DW, Beattie EJ. Discontinuous or “skip” metastases in breast carcinoma. Analysis of 1228 axillary dissections. Ann Surg. 1983;197:276–83.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Veronesi U, Rilke F, Luini A, Sacchini V, Galimberti V, Campa T, et al. Distribution of axillary node metastases by level of invasion. An analysis of 539 cases. Cancer. 1987;59:682–7.CrossRefPubMedGoogle Scholar
  17. 17.
    Danforth DN, Findlay PA, McDonald HD, Lippman ME, Reichert CM, d’Angelo T, et al. Complete axillary lymph node dissection for stage I-II carcinoma of the breast. J Clin Oncol. 1986;4:655–62.PubMedGoogle Scholar
  18. 18.
    Fowble B, Solin LJ, Schultz DJ, Goodman RL. Frequency, sites of relapse, and outcome of regional node failures following conservative surgery and radiation for early breast cancer. Int J Radiat Oncol Biol Phys. 1989;17:703–10.CrossRefPubMedGoogle Scholar
  19. 19.
    Veronesi U, Paganelli G, Viale G, Luini A, Zurrida S, Galimberti V, et al. Sentinel-lymph-node biopsy as a staging procedure in breast cancer: update of a randomised controlled study. Lancet Oncol. 2006;7:983–90.CrossRefPubMedGoogle Scholar
  20. 20.
    Zavagno G, De Salvo GL, Scalco G, Bozza F, Barutta L, Del Bianco P, GIVOM Trialists, et al. A Randomized clinical trial on sentinel lymph node biopsy versus axillary lymph node dissection in breast cancer: results of the Sentinella/GIVOM trial. Ann Surg. 2008;247:207–13.CrossRefPubMedGoogle Scholar
  21. 21.
    Krag DN, Anderson SJ, Julian TB, Brown AM, Harlow SP, Constantino JP, et al. Sentinel lymph node resection compared with conventional axillary lymph node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial. Lancet Oncol. 2010;11:927–33.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Ahmed M, Purushotham AD, Douek M. Novel techniques for sentinel lymph node biopsy in breast cancer: a systematic review. Lancet Oncol. 2014;15:e351–62.CrossRefPubMedGoogle Scholar
  23. 23.
    Yen TW, Hunt KK, Ross MI, Mirza NQ, Babiera GV, Meric-Bernstam F, et al. Predictors of invasive breast cancer in patients with an initial diagnosis of ductal carcinoma in situ: a guide to selective use of sentinel lymph node biopsy in management of ductal carcinoma in situ. J Am Coll Surg. 2005;200:516–26.CrossRefPubMedGoogle Scholar
  24. 24.
    Giuliano AE, Hunt KK, Ballman KV, Beitsch PD, Whitworth PW, Blumencranz PW, et al. Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. JAMA. 2011;305:569–75.CrossRefPubMedGoogle Scholar
  25. 25.
    Galimberti V, Cole BF, Zurrida S, Viale G, Luini A, Veronesi P, International Breast Cancer Study Group Trial 23-01 investigators, et al. Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23-01): a phase 3 randomised controlled trial. Lancet Oncol. 2013;14:297–305.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Xing Y, Foy M, Cox DD, Kuerer HM, Hunt KK, Cormier JN. Meta-analysis of sentinel lymph node biopsy after preoperative chemotherapy in patients with breast cancer. Br J Surg. 2006;93:539–46.CrossRefPubMedGoogle Scholar
  27. 27.
    Kelly AM, Dwamena B, Cronin P, Carlos RC. Breast cancer sentinel node identification and classification after neoadjuvant chemotherapy—systematic review and meta analysis. Acad Radiol. 2009;16:551–63.CrossRefPubMedGoogle Scholar
  28. 28.
    van Deurzen CH, Vriens BE, Tjan-Heijnen VC, van der Wall E, Albregts M, van Hilligersberg R, et al. Accuracy of sentinel node biopsy after neoadjuvant chemotherapy in breast cancer patients: a systematic review. Eur J Cancer. 2009;45:3124–30.CrossRefPubMedGoogle Scholar
  29. 29.
    Classe JM, Bordes V, Campion L, Mignotte H, Dravet F, Leveque J, et al. Sentinel lymph node biopsy after neoadjuvant chemotherapy for advanced breast cancer: results of Ganglion Sentinelle et Chimiotherapie Neoadjuvante, a French prospective multicentric study. J Clin Oncol. 2009;27:726–32.CrossRefPubMedGoogle Scholar
  30. 30.
    Boughey JC, Suman VJ, Mittendorf EA, Ahrendt GM, Wilke LG, Taback B, et al. Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial. JAMA. 2013;310(14):1455–61.CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Kuehn T, Bauerfeind I, Fehm T, Fleige B, Hausschild M, Helms G, et al. Sentinel lymph node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA). Lancet Oncol. 2013;14:609–18.CrossRefPubMedGoogle Scholar
  32. 32.
    Torresan RZ, Cabello C, Conde DM, Brenelli HB. Impact of the preservation of the intercostobrachial nerve in axillary lymphadenectomy due to breast cancer. Breast J. 2003;9:389–92.CrossRefPubMedGoogle Scholar
  33. 33.
    McNeely ML, Campbell K, Ospina M, Rowe BH, Dabbs K, Klassen TP, et al. Exercise interventions for upper-limb dysfunction due to breast cancer treatment. Cochrane Database Syst Rev. 2010. doi: 10.1002/14651858.CD005211.pub2.Google Scholar
  34. 34.
    Kitamura K, Iwase S, Kuroda Y, Yamaguchi T, Yamamoto D, Odagiri H, et al. A practice guideline for the management of lymphoedema. J Lymphoedema. 2011;6:60–71.Google Scholar
  35. 35.
    Nakajima H, Fujiwara I, Mizuta N, Sakaguchi K, Hachimine Y, Magae J. Video-assisted skin-sparing breast-conserving surgery for breast cancer and immediate reconstruction with autologous tissue: clinical outcomes. Ann Surg Oncol. 2009;16:1982–9.CrossRefPubMedGoogle Scholar
  36. 36.
    Ito T, Oura S, Yamamoto N, Nagamine S, Takahashi M, Tanino H, et al. Radiofrequency ablation (RFA) of breast cancer: A multicenter retrospective analysis. J Clin Oncol 2012;30: suppl; abstr 1119.Google Scholar
  37. 37.
    Sharma R, Rourke LL, Kronowitz SJ, Oh JL, Lucci A, Litton JK, et al. Management of local-regional recurrence following immediate breast reconstruction in patients with early breast cancer treated without postmastectomy radiotherapy. Plast Reconstr Surg. 2011;127:1763–72.CrossRefPubMedGoogle Scholar
  38. 38.
    Venus MR, Prinsloo DJ. Immediate breast reconstruction with latissimus dorsi flap and implant: audit of outcomes and patient satisfaction survey. J Plast Reconstr Aesthet Surg. 2010;63:101–5.CrossRefPubMedGoogle Scholar
  39. 39.
    Azzawi K, Ismaile A, Earl H, Forouhi P, Malata CM. Influence of neoadjuvant chemotherapy on outcomes of immediate breast reconstruction. Plast Reconstr Surg. 2010;126:1–11.CrossRefPubMedGoogle Scholar
  40. 40.
    Giacalone PL, Rathat G, Daures JP, Benos P, Azria D, Rouleau C. New concept for immediate breast reconstruction for invasive cancers: feasibility, oncological safety and esthetic outcome of post-neoadjuvant therapy immediate breast reconstruction versus delayed breast reconstruction: a prospective pilot study. Breast Cancer Treat. 2010;122:439–51.CrossRefGoogle Scholar
  41. 41.
    Khan SA, Stewart AK, Morrow M. Does aggressive local therapy improve survival in metastatic breast cancer? Surgery. 2002;132:620–6.CrossRefPubMedGoogle Scholar
  42. 42.
    Shien T, Kinoshita T, Shimizu C, Hojo T, Taira N, Doihara H, et al. Primary tumor resection improves the survival of younger patients with metastatic breast cancer. Oncol Rep. 2009;21:827–32.PubMedGoogle Scholar
  43. 43.
    Khan SA. De novo Stage IV breast cancer: breast conserving resection of the primary tumor? J Surg Oncol. 2014;110:51–7.CrossRefPubMedGoogle Scholar
  44. 44.
    Shen S-C, Liao C-H, Lo Y-F, Tsai H-P, Kuo W-L, Yu C-C, et al. Favorable outcome of secondary axillary dissection in breast cancer patients with axillary nodal relapse. Ann Surg Oncol. 2012;19:1122–8.CrossRefPubMedGoogle Scholar
  45. 45.
    Pergolizzi S, Settineri N, Russi E, Maisano R, Adamo V, Santacaterina A, et al. Supraclavicular lymph node metastases (SLM) from breast cancer as only site of distant disease: has radiology any role? Anticancer Res. 1997;17:2303–8.PubMedGoogle Scholar
  46. 46.
    Welter S, Jacobs J, Krbek T, Totsch M, Stamatis G. Pulmonary metastases of breast cancer. When is resection indicated? Eur J Cardiothorac Surg. 2008;34:1228–34.CrossRefPubMedGoogle Scholar
  47. 47.
    Dürr HR, Müller PE, Lenz T, Baur A, Jansson V, Refior HJ. Surgical treatment of bone metastases in patients with breast cancer. Clin Orthop Relat Res. 2002;396:191–6.CrossRefPubMedGoogle Scholar
  48. 48.
    Hoffmann K, Franz C, Hinz U, Schirmacher P, Ferfarth C, Eichbaum M, et al. Liver resection for multimodal treatment of breast cancer metastases: identification of prognostic factors. Ann Surg Oncol. 2010;17:1546–54.CrossRefPubMedGoogle Scholar
  49. 49.
    Boogerd W, Vos VW, Hart AA, Baris G. Brain metastases in breast cancer; natural history, prognostic factors and outcome. J Neurooncol. 1993;15:165–74.CrossRefPubMedGoogle Scholar
  50. 50.
    Altundag K, Bondy ML, Mirza NQ, Kau SW, Broglio K, Hortobagyi GN, et al. Clinicopathologic characteristics and prognostic factors in 420 metastatic breast cancer patients with central nervous system metastasis. Cancer. 2007;110:2640–7.CrossRefPubMedGoogle Scholar
  51. 51.
    Mahmoud-Ahmed AS, Suh JH, Lee SY, Crownover RL, Barnett GH. Results of whole brain radiotherapy in patients with brain metastases from breast cancer: a retrospective study. Int J Radiat Oncol Biol Phys. 2002;54:810–7.CrossRefPubMedGoogle Scholar
  52. 52.
    Aoyama H. Radiation therapy for brain metastases in breast cancer patients. Breast Cancer. 2011;18:244–51.CrossRefPubMedGoogle Scholar
  53. 53.
    Morgan J, Wyld L, Collins KA, Reed MW. Surgery versus primary endocrine therapy for operable primary breast cancer in elderly women (70 years plus). Cochrane Database Syst Rev. 2014. doi: 10.1002/14651858.CD004272.pub3.Google Scholar
  54. 54.
    Tejirian T, DiFronzo LA, Haigh PI. Antibiotic prophylaxis for preventing wound infection after breast surgery: a systematic review and metaanalysis. J Am Coll Surg. 2006;203:729–34.CrossRefPubMedGoogle Scholar
  55. 55.
    Jones DJ, Bunn F, Bell-Syer SV. Prophylactic antibiotics to prevent surgical site infection after breast cancer surgery. Cochrane Database Syst Rev. 2014;3:CD005360.PubMedGoogle Scholar
  56. 56.
    de Bresser J, de Vos B, van der Ent F, Hulsewe K. Breast MRI in clinically and mammographically occult breast cancer presenting with an axillary metastasis: a systematic review. Eur J Surg Oncol. 2010;36:114–9.CrossRefPubMedGoogle Scholar
  57. 57.
    Varadarajan R, Edge SB, Yu J, Watroba N, Janarthanan BR. Prognosis of occult breast carcinoma presenting as isolated axillary nodal metastasis. Oncology. 2006;71:456–9.CrossRefPubMedGoogle Scholar
  58. 58.
    van Ooijen B, Bontenbal M, Henzen-Logmans SC, Koper PC. Axillary nodal metastases from an occult primary consistent with breast carcinoma. Br J Surg. 1993;80:1299–300.CrossRefPubMedGoogle Scholar
  59. 59.
    Dworkin RH, O’Connor AB, Backonja M, Farrar JT, Finnerup NB, Jensen TS, et al. Pharmacologic management of neuropathic pain: evidence-based recommendations. Pain. 2007;132:237–51.CrossRefPubMedGoogle Scholar
  60. 60.
    Jang JH, Choi MY, Lee SK, et al. Clinicopathologic risk factors for the local recurrence of phyllodes tumors of the breast. Ann Surg Oncol. 2012;19:2612–7.CrossRefPubMedGoogle Scholar
  61. 61.
    Kapiris I, Nasiri N, A’Hern R, et al. Outcome and predictive factors of local recurrence and distant metastases following primary surgical treatment of high-grade malignant phyllodes tumours of the breast. Eur J Surg Oncol. 2001;27:723–30.CrossRefPubMedGoogle Scholar

Copyright information

© The Japanese Breast Cancer Society 2016

Authors and Affiliations

  • Hiromitsu Jinno
    • 1
    Email author
  • Masafumi Inokuchi
    • 2
  • Toshikazu Ito
    • 3
  • Kaoru Kitamura
    • 4
  • Goro Kutomi
    • 5
  • Takehiko Sakai
    • 6
  • Yuko Kijima
    • 7
  • Noriaki Wada
    • 8
  • Yoshinori Ito
    • 9
  • Hirofumi Mukai
    • 8
  1. 1.Department of SurgeryTeikyo University School of MedicineTokyoJapan
  2. 2.Department of Breast OncologyKanazawa University HospitalIshikawaJapan
  3. 3.Department of SurgeryRinku General Medical CenterOsakaJapan
  4. 4.Department of Breast SurgeryNagumo Clinic FukuokaFukuokaJapan
  5. 5.Department of Surgery, Surgical Oncology and ScienceSapporo Medical University Hospital HokkaidoSapporoJapan
  6. 6.Breast Oncology CenterCancer Institute Hospital of the Japanese Foundation for Cancer ResearchTokyoJapan
  7. 7.Department of Digestive Surgery, Breast and Thyroid SurgeryKagoshima University School of MedicineKagoshimaJapan
  8. 8.Department of General and Breast SurgeryTokyo Dental College Ichikawa General HospitalChibaJapan
  9. 9.Department of Breast Medical OncologyThe Cancer Institute Hospital of Japanese Foundation for Cancer ResearchTokyoJapan

Personalised recommendations